Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 7/20 | 0.70 |
| ▸ | PDE3B | Q13370 | 6/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | PDE4A | P27815 | 2/20 | 0.70 |
| ▸ | BLM | P54132 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | PDE5A | O76074 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GALR3 | O60755 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | PDE2A | O00408 | 1/20 | 0.53 |
| ▸ | PDE1A | P54750 | 1/20 | 0.53 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Milrinone SCHEMBL9301167 | 0.82 | PDE3A (1.00) | PDE3APDE3BKDM4EHPGDPDE4A | |
| Milrinone SCHEMBL9309054 | 0.82 | PDE3A (1.00) | PDE3APDE3BKDM4EHPGDPDE4A | |
| Milrinone SCHEMBL36947 | 0.82 | PDE3A (1.00) | PDE3APDE3BKDM4EHPGDPDE4A | |
| Milrinone SCHEMBL9247989 | 0.82 | PDE3A (1.00) | PDE3APDE3BKDM4EHPGDPDE4A | |
| Milrinone SCHEMBL28184205 | 0.81 | PDE3A (0.97) | PDE3APDE3BKDM4EHPGDPDE4A | |
| SCHEMBL10911458 | 0.81 | PDE3A (0.71) | PDE3APDE3BKDM4EHPGDPDE4A | |
| Milrinone SCHEMBL1160021 | 0.80 | PDE3A (0.94) | PDE3APDE3BKDM4EHPGDPDE4A | |
| Milrinone SCHEMBL9132559 | 0.80 | PDE3A (0.94) | PDE3APDE3BKDM4EHPGDPDE4A | |
| SCHEMBL10984156 | 0.78 | PDE3A (0.67) | PDE3APDE3BKDM4EHPGDPDE4A | |
| SCHEMBL9276923 | 0.78 | KDM4E (0.53) | PDE3APDE3BKDM4EHPGDPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053350-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2013-02-28 | — | — | US | claimed |
| US-20240366620-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-11-07 | — | — | US | disclosed |
| EP-3334404-B1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A AND SLFN12 | BROAD INST INC (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12053476-B2 | Compounds, compositions and methods for cancer patient stratification and cancer treatment | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-08-06 | — | — | US | disclosed |
| CN-114886851-B | Milrinon liposome, preparation and preparation method thereof | 平顶山市第二人民医院 | 2023-04-25 | — | — | CN | disclosed |
| CN-114886851-A | Milrinone liposome, preparation and preparation method thereof | 平顶山市第二人民医院 | 2022-08-12 | — | — | CN | disclosed |
| CN-108883112-B | Compounds, compositions and methods for cancer patient stratification and cancer treatment | 拜耳医药股份公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114699528-A | Compositions and methods for PDE3A or SLFN12 expressing cancers | 布罗德研究所股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114617843-A | Milrinone injection and preparation method and application thereof | 华润三九（雅安）药业有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114601837-A | Compounds, compositions and methods for cancer patient stratification and cancer treatment | 拜耳医药股份公司 | 2022-06-10 | — | — | CN | disclosed |
| US-8912335-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2014093114-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20130296331-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING RENAL DYSFUNCTION INDUCED BY RENAL HYPOPERFUSION OR ACUTE KIDNEY INJURY | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-11-07 | — | — | US | disclosed |
| US-20130053350-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120322728-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120316138-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120309975-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2513070-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | Metabolic Solutions Development Company LLC (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-2512475-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | Metabolic Solutions Development Company LLC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20070274925-A1 | NEBULIZABLE COMPOSITIONS OF QUATERNARY AMMONIUM MUSCARINIC RECEPTOR ANTAGONISTS | DEY, L.P. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053350-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PPARD, PPARG, PPARA | PDE3A 1698/4885PDE3B 1548/4885KDM4E 3326/4885 |
| US-20120309975-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | PPARD, PPARG, PPARA | PDE3A 2374/4885PDE3B 2005/4885KDM4E 3252/4885 |
| US-20070274925-A1 | NEBULIZABLE COMPOSITIONS OF QUATERNARY AMMONIUM MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | PDE3A 475/4885PDE3B 463/4885KDM4E 2735/4885 |
| US-20120316138-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | PPARD, PPARA, PPARG | PDE3A 1128/4885PDE3B 734/4885KDM4E 2796/4885 |
| US-12053476-B2 | Compounds, compositions and methods for cancer patient stratification and cancer treatment | CREB1, CREBBP, SLFN12 | PDE3A 7/4885PDE3B 11/4885KDM4E 2202/4885 |
| US-20120322728-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | GLP1R, PPARD, PPARA | PDE3A 882/4885PDE3B 770/4885KDM4E 3073/4885 |
| US-20130296331-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING RENAL DYSFUNCTION INDUCED BY RENAL HYPOPERFUSION OR ACUTE KIDNEY INJURY | PDE3B, PDE3A, PDE2A | PDE3A 2/4885PDE3B 1/4885KDM4E 2463/4885 |
| US-20240366620-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | CREB1, CREBBP, SLFN12 | PDE3A 7/4885PDE3B 11/4885KDM4E 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.